TYK MEDICINES-B (02410) has disclosed that on February 27, 2026, after trading hours, existing shareholders, including the company, along with TYK Bio and subscribers, entered into a capital increase agreement. The parties have consented to augment the registered capital of TYK Bio by approximately RMB 6.49 million for a total consideration of about RMB 83.5 million. Upon completion of the capital increase, the total registered capital of TYK Bio will rise from RMB 14 million to roughly RMB 20.49 million. Consequently, the company's stake in TYK Bio will decrease from about 57.14% to 39.03%, and TYK Bio will cease to be a subsidiary of the group.

The group is a biopharmaceutical company approaching the commercialization phase. TYK Bio, a non-wholly-owned subsidiary, focuses on bispecific antibodies, trispecific antibodies, and antibody-drug conjugates, operating independently from the group's core business and operations. The current capital increase, along with prior injections, is anticipated to provide working capital for TYK Bio. As an early-stage startup, TYK Bio is projected to have substantial funding requirements in the near future before achieving commercialization. Therefore, these transactions will enable the group to concentrate its resources on other aspects of its operations, allowing for improved management while maintaining a significant interest and involvement in TYK Bio.